Physician profile
Gerardo Parada
NPI 1407820194
$8,750.83
in general payments reported to CMS, 2019-2025
26 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $129 · 2021: $504 · 2022: $1,246 · 2023: $3,020 · 2024: $1,669 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,880 · Travel and Lodging: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,879.67 |
| Travel and Lodging | $379.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,743.43 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Glaukos Corporation | $1,456.98 | 2019-2025 | Idosetr, Istent Infinite, Istent Trabecular Micro-Bypass System Model Is3 |
| Biotissue Holdings INC. | $1,348.23 | 2022-2025 | |
| Abbvie INC. | $761.45 | 2022-2025 | |
| Tearlab Corp | $461.06 | 2021-2024 | Scoutpro Osmolarity System |
| Bausch & Lomb Americas INC. | $384.26 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $373.43 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $251.89 | 2019-2021 | |
| Allergan, INC. | $208.53 | 2020-2022 | |
| Rxsight INC | $202.28 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Mallinckrodt Hospital Products INC. | $197.64 | 2021-2023 | Acthar |
| Amgen INC. | $176.73 | 2024-2025 | Tepezza |
| New World Medical,INC. | $133.51 | 2022 | |
| Eyepoint US, INC. | $127.79 | 2022 | |
| Alimera Sciences, INC. | $127.49 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $119.02 | 2023 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.45 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $110.28 | 2021 | |
| Sun Pharmaceutical Industries INC. | $107.41 | 2022-2023 | Cequa |
| Dompe US, INC. | $101.36 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $89.14 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $58.93 | 2024 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $36.98 | 2022 | |
| Astellas Pharma US INC | $22.17 | 2024 | Izervay |
| Kala Pharmaceuticals, INC. | $21.62 | 2021 | |
| Lensar, INC. | $16.77 | 2025 | Lensar Laser System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Parada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.